Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 ...
- Single-step CD45-engager technology shows robust immune evasion with functional persistence in pre-clinical models - Phase 1 study to evaluate ‘off-the-shelf’ natural killer cell cancer ...
Peking University scientists have developed a cancer therapy that could make life-saving treatment accessible to any patient, anywhere. A team led by Professor Wei Wensheng from Peking University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback